Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · BLISSGVS

BLISSGVS PH

HealthcarePharmaceuticals & Biotechnology₹7170 cr market cap
₹665.35 ▼ -2.2% today As of 19 Nov 2026
52-week low ₹142.7652-week high ₹737.65

-7.8% from the 52-week high · +376.6% above the low

Bliss GVS Pharma Ltd. engages in the development, manufacture, and marketing of pharmaceutical formulations. The company is headquartered in Mumbai, Maharashtra and currently employs 763 full-time employees. The company went IPO on 2010-07-26. The Company’s product categories include pharma products and other healthcare products. Its pharma products include pharma products include capsules, creams, gels, ointments, dry powder for injection, effervescent tablets, eye/ear drops, nasal solution, lotions, lozenges, soft gelatine capsules and syrups. The Company’s other healthcare products include balm, nasal inhaler, solution, soap, vaginal wash, roll on, shampoo, powder, spray, and petroleum jelly. Its brands include ANOMEX, ANOMEX DS, CONLAX 5/10, G - ALFENAC 100, GACET 80/125/170/250/500/1G, GMETH - 50/100, GSUNATE - 50/100/200, GVCAM - 7.5/15, GV-SOFT 1/2/3/4 G, LOFNAC - 12.5/25/50/100, MEFINOL, MELANEZ, MENINA - 25/100, TYRIDOL, VIGOTAMIN, COMIT 50, BG - CLIND, VAGID CL, ECOZOLE, GVGYL 500, GYNANFORT, GVGYL N, KLOVINAL, LONART, LONART FORTE, LONART Dispersible, FINMOL, GACET-500, and DOXYCYCLINE.

The short version. BLISSGVS PH reported revenue of ₹313 crore for Sep 2026, up 28.3% from a year earlier. Net profit was ₹52 crore (up 92.6% year on year). Return on equity was 10.8% in Mar 2026. Promoter holding was 50.07% in Sep 2026, up 14.97 points over 8 quarters.

1 · The price

How has the stock traded?

BLISSGVS PH trades 7.8% below its 52-week high and 376.6% above its 52-week low.

Change over period: —

1M+8.5%
3M+18.6%
6M+134.6%
1Y+310.1%

2 · The business

Is it growing?

Sales, year on year+28.3%

Sep 2026 revenue of ₹313 cr.

Profit, year on year+92.6%

Sep 2026 net profit of ₹52 cr.

Net margin16.7%

5.6 pts higher than a year earlier.

3-year growth22.1% profit

Revenue compounded at 9.2% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue313286257218244207198210
Net profit5250362327431624
Net margin %16.717.513.810.711.120.77.811.3
EPS (₹)4.914.723.362.22.584.081.472.26

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue927810770752747577689898
Net profit129847571156897124
Net margin %13.910.49.89.42.011.914.113.8
EPS (₹)12.218.07.216.81.456.649.4312.96

3 · The quality

How well does it turn capital into profit?

Return on equity was 10.8% in Mar 2026; debt to equity is 0.00.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %10.88.07.88.0
Return on capital %16.011.811.712.1
EBITDA margin %23.519.318.817.6
Net margin %12.910.09.49.2

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR9.2%10.9%
Profit CAGR22.1%13.5%
Debt to equity0.00
Interest cover16.8x
Current ratio4.02
P/E ratio45.7

4 · The owners

Who holds it, and are they adding?

Promoter holding50.07%

Up 14.97 pts over 8 quarters.

Foreign institutions5.03%

Down 8.48 pts over 8 quarters.

Domestic institutions9.62%

Up 3.07 pts over 8 quarters.

Mutual fund schemes2

+0 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter35.135.2935.4435.3935.3635.3635.0150.07+14.97
FII13.5113.1812.6513.2714.5410.458.075.03-8.48
DII6.556.556.545.985.785.049.479.62+3.07
Public44.8444.9845.3645.3644.3249.1547.4535.28-9.56

Mutual fund holdings · Oct 2026

2 schemes hold this stock

2 the month before.

  • Motilal Oswal BSE Healthcare ETF0.27% of NAV
  • Bandhan BSE Healthcare Index Fund0.27% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for BLISSGVS PH are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about BLISSGVS PH

What is the BLISSGVS PH share price?

BLISSGVS PH (BLISSGVS) last closed at ₹665.35, down 2.2% on the day. Its 52-week range is ₹142.76 to ₹737.65.

What is the market cap of BLISSGVS PH?

BLISSGVS PH has a market capitalisation of about ₹7,170 crore. Its price-to-earnings ratio is 45.7.

How are BLISSGVS PH's latest results?

BLISSGVS PH reported revenue of ₹313 crore for Sep 2026, up 28.3% from a year earlier. Net profit was ₹52 crore (up 92.6% year on year). Return on equity was 10.8% in Mar 2026. Promoter holding was 50.07% in Sep 2026, up 14.97 points over 8 quarters.

Who owns BLISSGVS PH?

As of Sep 2026, shareholding was: Promoter 50.07%, FII 5.03%, DII 9.62%, Public 35.28%.

How many mutual funds hold BLISSGVS PH?

2 mutual fund schemes held BLISSGVS PH in October 2026. That compares with 2 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 08 Jul 2026 · Final Dividend - Rs. 1
  • 18 Feb 2026 · Interim Dividend - Rs. 0.5
  • 24 Jul 2025 · Final Dividend - Rs. 0.5
  • 18 Jul 2024 · Final Dividend - Rs. 0.5
  • 12 Jul 2023 · Final Dividend - Rs. 0.5
  • 20 Jun 2022 · Final Dividend - Rs. 0.5

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.